Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. The company is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet. It has license agreements with Northwestern University, New York University and the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone305-420-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees21
Next Earnings Date3/13/2019 (Estimated)
OptionableOptionable
Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions
What is Catalyst Pharmaceuticals' stock symbol?
Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."
How were Catalyst Pharmaceuticals' earnings last quarter?
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) announced its quarterly earnings results on Friday, August, 10th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.02. View Catalyst Pharmaceuticals' Earnings History.
When is Catalyst Pharmaceuticals' next earnings date?
What price target have analysts set for CPRX?
4 equities research analysts have issued 1 year target prices for Catalyst Pharmaceuticals' stock. Their predictions range from $6.00 to $9.00. On average, they expect Catalyst Pharmaceuticals' stock price to reach $7.1250 in the next year. This suggests a possible upside of 144.8% from the stock's current price. View Analyst Price Targets for Catalyst Pharmaceuticals.
What is the consensus analysts' recommendation for Catalyst Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalyst Pharmaceuticals.
What are Wall Street analysts saying about Catalyst Pharmaceuticals stock?
Here are some recent quotes from research analysts about Catalyst Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Catalyst is developing Firdapse, which is the only candidate in late-stage development, for additional indications. All the other candidates are in early stages of development. Thus, the successful development and commercialization of drug candidates is highly crucial for the company. The company’s share price movement shows that the stock has underperformed the industry year to date. Loss estimates have widened ahead of the Q4 earnings release. The company has an average positive earnings surprise history. However, In November 2018, Firdapse was approved by the FDA for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) in adults. Firdapse is the first approved product for Catalyst and thus is a big boost for the company. With the approval, the company will start generating revenues. Firdapse becomes the first FDA approved treatment for LEMS." (2/13/2019)
- 2. HC Wainwright analysts commented, "We raised our PT to $9 from $6 in view of the additional color on the commercial front. We adjusted the launch cost of and lowered the peak penetration from 25% to 18%." (12/14/2018)
- 3. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and $8 PT on CPRX. This morning BMO, Catalyst hosted an earnings call and reported 3Q18 expenses of $8.2M and cash & investments of $66.7M. Our model projects sufficient cash to fund operations through the anticipated Firdapse launch in 2019. Questions on the call centered on potential near-term Firdapse approval (PDUFA goal date Nov. 28), as well as go-to-market strategy, including patient access and pricing. Additionally, the company now plans to expand to the Canadian market (just announced)." (11/8/2018)
Has Catalyst Pharmaceuticals been receiving favorable news coverage?
News articles about CPRX stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catalyst Pharmaceuticals earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next few days.
Are investors shorting Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 6,579,722 shares, an increase of 48.7% from the December 31st total of 4,424,908 shares. Based on an average trading volume of 1,376,572 shares, the short-interest ratio is currently 4.8 days. Currently, 7.0% of the shares of the company are short sold. View Catalyst Pharmaceuticals' Current Options Chain.
Who are some of Catalyst Pharmaceuticals' key competitors?
Some companies that are related to Catalyst Pharmaceuticals include Amphastar Pharmaceuticals (AMPH), Wave Life Sciences (WVE), Deciphera Pharmaceuticals (DCPH), Vanda Pharmaceuticals (VNDA), CannTrust (CNTTF), Rhythm Pharmaceuticals (RYTM), Puma Biotechnology (PBYI), Alder Biopharmaceuticals (ALDR), Tricida (TCDA), Epizyme (EPZM), Kiniksa Pharmaceuticals (KNSA), MacroGenics (MGNX), Advanz Pharma (CXRXF), Homology Medicines (FIXX) and Retrophin (RTRX).
What other stocks do shareholders of Catalyst Pharmaceuticals own?
Who are Catalyst Pharmaceuticals' key executives?
Catalyst Pharmaceuticals' management team includes the folowing people:
- Mr. Patrick J. McEnany, Co-Founder, Chairman, CEO & Pres (Age 72)
- Ms. Alicia Grande, VP, CFO & Treasurer (Age 48)
- Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 57)
- Mr. Brian Elsbernd, Chief Legal & Compliance Officer (Age 55)
- Dr. Gary Ingenito, Chief Medical Officer (Age 63)
Who are Catalyst Pharmaceuticals' major shareholders?
Catalyst Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.79%), Broadfin Capital LLC (6.10%), Northern Trust Corp (1.10%), Geode Capital Management LLC (1.04%), Knott David M (0.60%) and Gables Capital Management Inc. (0.47%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Institutional Ownership Trends for Catalyst Pharmaceuticals.
Which major investors are selling Catalyst Pharmaceuticals stock?
Which major investors are buying Catalyst Pharmaceuticals stock?
CPRX stock was acquired by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, BlackRock Inc., Dimensional Fund Advisors LP, Two Sigma Investments LP, Virtu Financial LLC, Geode Capital Management LLC, Knott David M and Alps Advisors Inc.. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus and Patrick J Mcenany. View Insider Buying and Selling for Catalyst Pharmaceuticals.
How do I buy shares of Catalyst Pharmaceuticals?
Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Catalyst Pharmaceuticals' stock price today?
One share of CPRX stock can currently be purchased for approximately $2.91.
How big of a company is Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals has a market capitalization of $298.97 million. The biopharmaceutical company earns $-18,410,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Catalyst Pharmaceuticals employs 21 workers across the globe.
What is Catalyst Pharmaceuticals' official website?
How can I contact Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected]
MarketBeat Community Rating for Catalyst Pharmaceuticals (NASDAQ CPRX)
MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote "Outperform" if you believe CPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
